The Experts below are selected from a list of 29877 Experts worldwide ranked by ideXlab platform
Francesco Landi - One of the best experts on this subject based on the ideXlab platform.
-
the predictive value of the ewgsop definition of Sarcopenia results from the inchianti study
Journals of Gerontology Series A-biological Sciences and Medical Sciences, 2016Co-Authors: Lara Bianchi, Jack M Guralnik, Luigi Ferrucci, Antonio Cherubini, Marcello Maggio, Stefania Bandinelli, E Savino, Gloria Brombo, Giovanni Zuliani, Francesco LandiAbstract:Background Sarcopenia is associated with increased risk of adverse outcomes in older people. Aim of the study was to explore the predictive value of the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic algorithm in terms of disability, hospitalization, and mortality and analyze the specific role of grip strength and walking speed as diagnostic criteria for Sarcopenia. Methods Longitudinal analysis of 538 participants enrolled in the InCHIANTI study. Sarcopenia was defined as having low muscle mass plus low grip strength or low gait speed (EWGSOP criteria). Muscle mass was assessed using bioimpedance analysis. Cox proportional and logistic regression models were used to assess risk of death, hospitalization, and disability for sarcopenic people and to investigate the individual contributions of grip strength and walking speed to the predictive value of the EWGSOP's algorithm. Results Prevalence of EWGSOP-defined Sarcopenia at baseline was 10.2%. After adjusting for potential confounders, Sarcopenia was associated with disability (odds ratio 3.15; 95% confidence interval [CI] 1.41-7.05), hospitalization (hazard ratio [HR] 1.57; 95% CI 1.03-2.41), and mortality (HR 1.88; 95% CI 0.91-3.91). The association between an alternative sarcopenic phenotype, defined only by the presence of low muscle mass and low grip strength, and both disability and mortality were similar to the association with the phenotypes defined by low muscle mass and low walking speed or by the EWGSOP algorithm. Conclusions The EWGSOP's phenotype is a good predictor of incident disability, hospitalization and death. Assessment of only muscle weakness, in addition to low muscle mass, provided similar predictive value as compared to the original algorithm.
-
Sarcopenia and mortality risk in frail older persons aged 80 years and older results from ilsirente study
Age and Ageing, 2013Co-Authors: Alfonso J Cruzjentoft, Francesco Landi, Rosa Liperoti, Andrea Russo, Silvia Giovannini, Matteo Tosato, Ettore Capoluongo, Roberto Bernabei, Graziano OnderAbstract:Background and aims: Sarcopenia has been indicated as a reliable marker of frailty and poor prognosis among the oldest individuals. We evaluated the impact of Sarcopenia on the risk of all-cause death in a population of frail older persons living in community. Methods: we analysed data from the Aging and Longevity Study, a prospective cohort study that collected data on all subjects aged 80 years and older residing in the Sirente geographic area (n= 364). The present analysis was conducted among those subjects who were between 80 and 85 years of age at the time of the baseline assessment (n= 197). The main outcome measure was all-cause mortality over 7-year follow-up. According to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria, the diagnosis of Sarcopenia required the documentation of low muscle mass and the documentation of either low muscle strength or low physical performance. Cox proportional regression models were used to estimate crude and adjusted hazard ratios and 95% confidence intervals of death by the presence of Sarcopenia. Results: using the EWGSOP-suggested criteria, 43 subjects with Sarcopenia (21.8%) were identified. During the 7-year follow-up, 29 (67.4%) participants died among subjects with Sarcopenia compared with 63 subjects (41.2%) without Sarcopenia (P< 0.001). After adjusting for potential confounders including age, gender, education, activities of daily living (ADL) impairment, body mass index, hypertension, congestive heart failure, chronic obstructive pulmonary disease, number of diseases, TNF-α, participants with Sarcopenia had a higher risk of death for all causes compared with non-sarcopenic subjects (HR: 2.32, 95% CI: 1.01–5.43). Conclusions: our results obtained from a representative sample of very old and frail subjects show that Sarcopenia is associated with mortality, independently of age and other clinical and functional variables.
-
Sarcopenia as a risk factor for falls in elderly individuals results from the ilsirente study
Clinical Nutrition, 2012Co-Authors: Francesco Landi, Rosa Liperoti, Andrea Russo, Silvia Giovannini, Matteo Tosato, Ettore Capoluongo, Roberto Bernabei, Graziano OnderAbstract:Summary Background & aims Sarcopenia has been indicated as a reliable marker of frailty and poor prognosis among the oldest individuals. We evaluated the relationship between Sarcopenia and 2-year risk of falls in a population of persons aged 80 years or older. Methods Data are from the baseline and follow-up evaluations of the Aging and Longevity Study in the Sirente Geographic Area (ilSIRENTE Study) ( n = 260). According to the European Working Group on Sarcopenia in Older People (EWGSOP), Sarcopenia was diagnosed in presence of low muscle mass (mid-arm muscle circumference) plus either low muscle strength (hand grip) or low physical performance (4-m walking speed). The primary outcome measure was the incident falls during the follow-up period of 2 years. The relationship between Sarcopenia and incident falls was estimated by deriving hazard ratios (HRs) from multiple logistic regression models considering the dependent variable of interest at least one fall during the follow-up period. Results Sixty-six participants (25.4%) were identified as affected by Sarcopenia. Eighteen out of 66 (27.3%) participants with Sarcopenia and 19 out of 194 (9.8%) without Sarcopenia reported incident falls during the two-year follow-up of the study ( p Conclusions The present study suggests that Sarcopenia – assessed using the EWGSOP algorithm – is highly prevalent among elderly persons without gender differences (25%). Sarcopenic participants were over three times more likely to fall during a follow-up period of 2 years relative to non sarcopenic individuals, regardless of age, gender and other confounding factors.
-
prevalence and risk factors of Sarcopenia among nursing home older residents
Journals of Gerontology Series A-biological Sciences and Medical Sciences, 2012Co-Authors: Francesco Landi, Rosa Liperoti, Andrea Russo, Roberto Bernabei, Domenico Fusco, Simona Mastropaolo, Davide Quattrociocchi, Anna S Proia, Graziano OnderAbstract:Background and aims. Sarcopenia has been indicated as a reliable marker of frailty and poor prognosis among the oldest individuals. At present, there are no data on Sarcopenia in nursing home population. We evaluated the prevalence of Sarcopenia and its association with functional and clinical status in a population of elderly persons aged 70 years and older living in nursing homes. Methods. This study was conducted selecting all the participants (n = 122) living in the teaching nursing homes of Catholic University of Rome who were aged 70 years and older from August 1, 2010, to September 30, 2010. The European Working Group on Sarcopenia in Older People (EWGSOP) criteria were adopted. Accordingly, diagnosis of Sarcopenia required the documentation of low muscle mass plus the documentation of either low muscle strength or low physical performance. Results. Forty residents (32.8%) were identified as affected by Sarcopenia. The multivariate logistic regression analysis showed a high increase in risk of Sarcopenia for male residents (odds ratio [OR] 13.39; 95% confidence interval [CI] 3.51–50.63) and for residents affected by cerebrovascular disease (OR 5.16; 95% CI 1.03–25.87) or osteoarthritis (OR 7.24; 95% CI 2.02–25.95). Residents who had a body mass index higher than 21 kg/m 2 had a lower risk to be sarcopenic (OR 0.76; 95% CI 0.64–0.90) relative to those with body mass index less than 21 kg/m 2 . Similarly, Sarcopenia was less likely to be present among participants involved in leisure physical activity for 1 hour or more per day (OR 0.40; 95% CI 0.12–0.98). Conclusions. The present study suggests that among participants living in nursing homes, Sarcopenia is highly prevalent and it is more represented among male residents (68%) than among female residents (21%). Our findings support the hypothesis that muscle mass is strongly associated with nutritional status and physical activity in nursing homes, too.
-
Sarcopenia european consensus on definition and diagnosis
Age and Ageing, 2010Co-Authors: Alfonso J Cruzjentoft, Jean Pierre Baeyens, Yves Rolland, Jurgen M Bauer, Jean-pierre Michel, Yves Boirie, Tommy Cederholm, Finbarr C Martin, Francesco Landi, Stephane M SchneiderAbstract:The group met and addressed the following questions, using the medical literature to build evidence-based answers: (i) What is Sarcopenia? (ii) What parameters define Sarcopenia? (iii) What variables reflect these parameters, and what measurement tools and cut-off points can be used? (iv) How does Sarcopenia relate to cachexia, frailty and sarcopenic obesity? For the diagnosis of Sarcopenia, EWGSOP recommends using the presence of both low muscle mass + low muscle function (strength or performance). EWGSOP variously applies these characteristics to further define conceptual stages as 'preSarcopenia', 'Sarcopenia' and 'severe Sarcopenia'. EWGSOP reviewed a wide range of tools that can be used to measure the specific variables of muscle mass, muscle strength and physical performance. Our paper summarises currently available data defining Sarcopenia cut-off points by age and gender; suggests an algorithm for Sarcopenia case finding in older individuals based on measurements of gait speed, grip strength and muscle mass; and presents a list of suggested primary and secondary outcome domains for research. Once an operational definition of Sarcopenia is adopted and included in the mainstream of comprehensive geriatric assessment, the next steps are to define the natural course of Sarcopenia and to develop and define effective treatment.
Liangkung Chen - One of the best experts on this subject based on the ideXlab platform.
-
recent advances in Sarcopenia research in asia 2016 update from the asian working group for Sarcopenia
Journal of the American Medical Directors Association, 2016Co-Authors: Weiju Lee, Likuo Liu, Lining Peng, Liangkung Chen, Hidenori Arai, Masahiro AkishitaAbstract:Sarcopenia was recently classified a geriatric syndrome and is a major challenge to healthy aging. Affected patients tend to have worse clinical outcomes and higher mortality than those without Sarcopenia. Although there is general agreement on the principal diagnostic characteristics, initial thresholds for muscle mass, strength, and physical performance were based on data from populations of predominantly Europid ancestry and may not apply worldwide. The Asian Working Group for Sarcopenia (AWGS) issued regional consensus guidelines in 2014, and many more research studies from Asia have since been published; this review summarizes recent progress. The prevalence of Sarcopenia estimated by the AWGS criteria ranges between 4.1% and 11.5% of the general older population; however, prevalence rates were higher in Asian studies that used European Working Group on Sarcopenia in Older People cut-offs. Risk factors include age, sex, heart disease, hyperlipidemia, daily alcohol consumption, and low protein or vitamin intake; physical activity is protective. Adjusting skeletal muscle mass by weight rather than height is better in showing the effect of older age in Sarcopenia and identifying sarcopenic obesity; however, some Asian studies found no significant skeletal muscle loss, and muscle strength might be a better indicator. Although AWGS 2014 diagnostic cut-offs were generally well accepted, some may require further revision in light of conflicting evidence from some studies. The importance of Sarcopenia in diverse therapeutic areas is increasingly evident, with strong research interest in sarcopenic obesity and the setting of malignancy. Pharmacologic interventions have been unsatisfactory, and the core management strategies remain physical exercise and nutritional supplementation; however, further research is required to determine the most beneficial approaches.
-
comparisons of Sarcopenia defined by iwgs and ewgsop criteria among older people results from the i lan longitudinal aging study
Journal of the American Medical Directors Association, 2013Co-Authors: Weiju Lee, Likuo Liu, Lining Peng, Minghsien Lin, Liangkung ChenAbstract:Abstract Objective To compare clinical characteristics of Sarcopenia defined by the International Working Group on Sarcopenia (IWGS) and European Working Group on Sarcopenia in Older People (EWGSOP) criteria among older people in Taiwan. Design A prospective population-based community study. Setting I-Lan County of Taiwan. Participants A total of 100 young healthy volunteers and 408 elderly people. Intervention None. Measurements Anthropometry, skeletal muscle mass measured by dual x-ray absorptiometry, relative appendicular skeletal muscle index (RASM), percentage skeletal muscle index (SMI), 6-meter walking speed, and handgrip strength. Results The prevalence of Sarcopenia was 5.8% to 14.9% in men and 4.1% to 16.6% in women according to IWGS and EWGSOP criteria by using RASM or SMI as the muscle mass indices. The agreement of Sarcopenia diagnosed by IWGS and EWGSOP criteria was only fair by using either RASM or SMI (kappa = 0.448 by RASM, kappa = 0.471 by SMI). The prevalence of Sarcopenia was lower by the IWGS definition than the EWGSOP definition, but it was remarkably lower by using RASM than SMI in both criteria. Overall, sarcopenic individuals defined by SMI were older, had a higher BMI but similar total skeletal muscle mass, and had poorer muscle strength and physical performance than nonsarcopenic individuals. However, by using RASM, sarcopenic individuals had less total skeletal muscle mass but similar BMI than nonsarcopenic individuals. Multivariable logistic regression showed that age was the strongest associative factor for Sarcopenia in both IWGS and EWGSOP criteria. Obesity played a neutral role in Sarcopenia when it is defined by using RASM, but significantly increased the risk of Sarcopenia in both criteria by using SMI. Conclusion The agreement of Sarcopenia defined by IWGS and EWGSOP was only fair, and the prevalence varied largely by using different skeletal muscle mass indices. Proper selections for cutoff values of handgrip strength, walking speed, and skeletal muscle indices with full considerations of gender and ethnic differences were of critical importance to reach the universal diagnostic criteria for Sarcopenia internationally.
Jean-pierre Michel - One of the best experts on this subject based on the ideXlab platform.
-
Sarcopenia european consensus on definition and diagnosis
Age and Ageing, 2010Co-Authors: Alfonso J Cruzjentoft, Jean Pierre Baeyens, Yves Rolland, Jurgen M Bauer, Jean-pierre Michel, Yves Boirie, Tommy Cederholm, Finbarr C Martin, Francesco Landi, Stephane M SchneiderAbstract:The group met and addressed the following questions, using the medical literature to build evidence-based answers: (i) What is Sarcopenia? (ii) What parameters define Sarcopenia? (iii) What variables reflect these parameters, and what measurement tools and cut-off points can be used? (iv) How does Sarcopenia relate to cachexia, frailty and sarcopenic obesity? For the diagnosis of Sarcopenia, EWGSOP recommends using the presence of both low muscle mass + low muscle function (strength or performance). EWGSOP variously applies these characteristics to further define conceptual stages as 'preSarcopenia', 'Sarcopenia' and 'severe Sarcopenia'. EWGSOP reviewed a wide range of tools that can be used to measure the specific variables of muscle mass, muscle strength and physical performance. Our paper summarises currently available data defining Sarcopenia cut-off points by age and gender; suggests an algorithm for Sarcopenia case finding in older individuals based on measurements of gait speed, grip strength and muscle mass; and presents a list of suggested primary and secondary outcome domains for research. Once an operational definition of Sarcopenia is adopted and included in the mainstream of comprehensive geriatric assessment, the next steps are to define the natural course of Sarcopenia and to develop and define effective treatment.
-
Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.
Age and ageing, 2010Co-Authors: Alfonso José Cruz-jentoft, Jean Pierre Baeyens, Yves Rolland, Jurgen M Bauer, Jean-pierre Michel, Yves Boirie, Tommy Cederholm, Finbarr C Martin, Francesco Landi, Stephane M SchneiderAbstract:The European Working Group on Sarcopenia in Older People (EWGSOP) developed a practical clinical definition and consensus diagnostic criteria for age-related Sarcopenia. EWGSOP included representatives from four participant organisations, i.e. the European Geriatric Medicine Society, the European Society for Clinical Nutrition and Metabolism, the International Association of Gerontology and Geriatrics-European Region and the International Association of Nutrition and Aging. These organisations endorsed the findings in the final document. The group met and addressed the following questions, using the medical literature to build evidence-based answers: (i) What is Sarcopenia? (ii) What parameters define Sarcopenia? (iii) What variables reflect these parameters, and what measurement tools and cut-off points can be used? (iv) How does Sarcopenia relate to cachexia, frailty and sarcopenic obesity? For the diagnosis of Sarcopenia, EWGSOP recommends using the presence of both low muscle mass + low muscle function (strength or performance). EWGSOP variously applies these characteristics to further define conceptual stages as 'preSarcopenia', 'Sarcopenia' and 'severe Sarcopenia'. EWGSOP reviewed a wide range of tools that can be used to measure the specific variables of muscle mass, muscle strength and physical performance. Our paper summarises currently available data defining Sarcopenia cut-off points by age and gender; suggests an algorithm for Sarcopenia case finding in older individuals based on measurements of gait speed, grip strength and muscle mass; and presents a list of suggested primary and secondary outcome domains for research. Once an operational definition of Sarcopenia is adopted and included in the mainstream of comprehensive geriatric assessment, the next steps are to define the natural course of Sarcopenia and to develop and define effective treatment.
-
understanding Sarcopenia as a geriatric syndrome
Current Opinion in Clinical Nutrition and Metabolic Care, 2010Co-Authors: Alfonso J Cruzjentoft, Eva Topinkova, Francesco Landi, Jean-pierre MichelAbstract:PURPOSE OF REVIEW: Highly prevalent in the population older than 65 years and leading to poor outcomes (functional decline and its related consequences), Sarcopenia does not benefit yet either of a clear understanding of its pathophysiology or of precise clinical or biological markers allowing its identification. RECENT FINDINGS: The new scientific definition of 'geriatric syndromes' challenges the authors to review the current Sarcopenia literature, allowing them to affirm that Sarcopenia cannot be considered as an age-related disease but as a true 'geriatric syndrome'. More than 50% of the population older than 80 years suffer from this medical condition, which is linked to multiple causations: the ageing process itself, genetic susceptibility, certain life habits, changes in living conditions and a number of chronic diseases. Moreover, Sarcopenia favours poor outcomes such as mobility disorders, disability, poor quality of life and death. SUMMARY: Considering Sarcopenia as a geriatric syndrome allows us to request its recognition and assess its multiple risk factors, to implement a clinical and public health approach to the management of sarcopenic patients and population at risk and to disentangle the links among Sarcopenia, frailty, disability and mortality.
Stephane M Schneider - One of the best experts on this subject based on the ideXlab platform.
-
Sarcopenia european consensus on definition and diagnosis
Age and Ageing, 2010Co-Authors: Alfonso J Cruzjentoft, Jean Pierre Baeyens, Yves Rolland, Jurgen M Bauer, Jean-pierre Michel, Yves Boirie, Tommy Cederholm, Finbarr C Martin, Francesco Landi, Stephane M SchneiderAbstract:The group met and addressed the following questions, using the medical literature to build evidence-based answers: (i) What is Sarcopenia? (ii) What parameters define Sarcopenia? (iii) What variables reflect these parameters, and what measurement tools and cut-off points can be used? (iv) How does Sarcopenia relate to cachexia, frailty and sarcopenic obesity? For the diagnosis of Sarcopenia, EWGSOP recommends using the presence of both low muscle mass + low muscle function (strength or performance). EWGSOP variously applies these characteristics to further define conceptual stages as 'preSarcopenia', 'Sarcopenia' and 'severe Sarcopenia'. EWGSOP reviewed a wide range of tools that can be used to measure the specific variables of muscle mass, muscle strength and physical performance. Our paper summarises currently available data defining Sarcopenia cut-off points by age and gender; suggests an algorithm for Sarcopenia case finding in older individuals based on measurements of gait speed, grip strength and muscle mass; and presents a list of suggested primary and secondary outcome domains for research. Once an operational definition of Sarcopenia is adopted and included in the mainstream of comprehensive geriatric assessment, the next steps are to define the natural course of Sarcopenia and to develop and define effective treatment.
-
Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.
Age and ageing, 2010Co-Authors: Alfonso José Cruz-jentoft, Jean Pierre Baeyens, Yves Rolland, Jurgen M Bauer, Jean-pierre Michel, Yves Boirie, Tommy Cederholm, Finbarr C Martin, Francesco Landi, Stephane M SchneiderAbstract:The European Working Group on Sarcopenia in Older People (EWGSOP) developed a practical clinical definition and consensus diagnostic criteria for age-related Sarcopenia. EWGSOP included representatives from four participant organisations, i.e. the European Geriatric Medicine Society, the European Society for Clinical Nutrition and Metabolism, the International Association of Gerontology and Geriatrics-European Region and the International Association of Nutrition and Aging. These organisations endorsed the findings in the final document. The group met and addressed the following questions, using the medical literature to build evidence-based answers: (i) What is Sarcopenia? (ii) What parameters define Sarcopenia? (iii) What variables reflect these parameters, and what measurement tools and cut-off points can be used? (iv) How does Sarcopenia relate to cachexia, frailty and sarcopenic obesity? For the diagnosis of Sarcopenia, EWGSOP recommends using the presence of both low muscle mass + low muscle function (strength or performance). EWGSOP variously applies these characteristics to further define conceptual stages as 'preSarcopenia', 'Sarcopenia' and 'severe Sarcopenia'. EWGSOP reviewed a wide range of tools that can be used to measure the specific variables of muscle mass, muscle strength and physical performance. Our paper summarises currently available data defining Sarcopenia cut-off points by age and gender; suggests an algorithm for Sarcopenia case finding in older individuals based on measurements of gait speed, grip strength and muscle mass; and presents a list of suggested primary and secondary outcome domains for research. Once an operational definition of Sarcopenia is adopted and included in the mainstream of comprehensive geriatric assessment, the next steps are to define the natural course of Sarcopenia and to develop and define effective treatment.
Alfonso J Cruzjentoft - One of the best experts on this subject based on the ideXlab platform.
-
Sarcopenia and mortality risk in frail older persons aged 80 years and older results from ilsirente study
Age and Ageing, 2013Co-Authors: Alfonso J Cruzjentoft, Francesco Landi, Rosa Liperoti, Andrea Russo, Silvia Giovannini, Matteo Tosato, Ettore Capoluongo, Roberto Bernabei, Graziano OnderAbstract:Background and aims: Sarcopenia has been indicated as a reliable marker of frailty and poor prognosis among the oldest individuals. We evaluated the impact of Sarcopenia on the risk of all-cause death in a population of frail older persons living in community. Methods: we analysed data from the Aging and Longevity Study, a prospective cohort study that collected data on all subjects aged 80 years and older residing in the Sirente geographic area (n= 364). The present analysis was conducted among those subjects who were between 80 and 85 years of age at the time of the baseline assessment (n= 197). The main outcome measure was all-cause mortality over 7-year follow-up. According to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria, the diagnosis of Sarcopenia required the documentation of low muscle mass and the documentation of either low muscle strength or low physical performance. Cox proportional regression models were used to estimate crude and adjusted hazard ratios and 95% confidence intervals of death by the presence of Sarcopenia. Results: using the EWGSOP-suggested criteria, 43 subjects with Sarcopenia (21.8%) were identified. During the 7-year follow-up, 29 (67.4%) participants died among subjects with Sarcopenia compared with 63 subjects (41.2%) without Sarcopenia (P< 0.001). After adjusting for potential confounders including age, gender, education, activities of daily living (ADL) impairment, body mass index, hypertension, congestive heart failure, chronic obstructive pulmonary disease, number of diseases, TNF-α, participants with Sarcopenia had a higher risk of death for all causes compared with non-sarcopenic subjects (HR: 2.32, 95% CI: 1.01–5.43). Conclusions: our results obtained from a representative sample of very old and frail subjects show that Sarcopenia is associated with mortality, independently of age and other clinical and functional variables.
-
Sarcopenia european consensus on definition and diagnosis
Age and Ageing, 2010Co-Authors: Alfonso J Cruzjentoft, Jean Pierre Baeyens, Yves Rolland, Jurgen M Bauer, Jean-pierre Michel, Yves Boirie, Tommy Cederholm, Finbarr C Martin, Francesco Landi, Stephane M SchneiderAbstract:The group met and addressed the following questions, using the medical literature to build evidence-based answers: (i) What is Sarcopenia? (ii) What parameters define Sarcopenia? (iii) What variables reflect these parameters, and what measurement tools and cut-off points can be used? (iv) How does Sarcopenia relate to cachexia, frailty and sarcopenic obesity? For the diagnosis of Sarcopenia, EWGSOP recommends using the presence of both low muscle mass + low muscle function (strength or performance). EWGSOP variously applies these characteristics to further define conceptual stages as 'preSarcopenia', 'Sarcopenia' and 'severe Sarcopenia'. EWGSOP reviewed a wide range of tools that can be used to measure the specific variables of muscle mass, muscle strength and physical performance. Our paper summarises currently available data defining Sarcopenia cut-off points by age and gender; suggests an algorithm for Sarcopenia case finding in older individuals based on measurements of gait speed, grip strength and muscle mass; and presents a list of suggested primary and secondary outcome domains for research. Once an operational definition of Sarcopenia is adopted and included in the mainstream of comprehensive geriatric assessment, the next steps are to define the natural course of Sarcopenia and to develop and define effective treatment.
-
understanding Sarcopenia as a geriatric syndrome
Current Opinion in Clinical Nutrition and Metabolic Care, 2010Co-Authors: Alfonso J Cruzjentoft, Eva Topinkova, Francesco Landi, Jean-pierre MichelAbstract:PURPOSE OF REVIEW: Highly prevalent in the population older than 65 years and leading to poor outcomes (functional decline and its related consequences), Sarcopenia does not benefit yet either of a clear understanding of its pathophysiology or of precise clinical or biological markers allowing its identification. RECENT FINDINGS: The new scientific definition of 'geriatric syndromes' challenges the authors to review the current Sarcopenia literature, allowing them to affirm that Sarcopenia cannot be considered as an age-related disease but as a true 'geriatric syndrome'. More than 50% of the population older than 80 years suffer from this medical condition, which is linked to multiple causations: the ageing process itself, genetic susceptibility, certain life habits, changes in living conditions and a number of chronic diseases. Moreover, Sarcopenia favours poor outcomes such as mobility disorders, disability, poor quality of life and death. SUMMARY: Considering Sarcopenia as a geriatric syndrome allows us to request its recognition and assess its multiple risk factors, to implement a clinical and public health approach to the management of sarcopenic patients and population at risk and to disentangle the links among Sarcopenia, frailty, disability and mortality.
